State Board of Administration of Florida Retirement System acquired a new position in Talaris Therapeutics, Inc. (NASDAQ:TALS – Get Rating) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 14,260 shares of the company's stock, valued at approximately $64,000.
Other hedge funds also recently modified their holdings of the company. Amalgamated Bank bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $31,000. Prospera Financial Services Inc bought a new stake in shares of Talaris Therapeutics in the 1st quarter worth approximately $50,000. Values First Advisors Inc. bought a new stake in shares of Talaris Therapeutics in the 2nd quarter worth approximately $53,000. JPMorgan Chase & Co. lifted its position in shares of Talaris Therapeutics by 26.3% in the 1st quarter. JPMorgan Chase & Co. now owns 14,826 shares of the company's stock worth $146,000 after acquiring an additional 3,090 shares during the period. Finally, New York State Common Retirement Fund lifted its position in shares of Talaris Therapeutics by 45.2% in the 1st quarter. New York State Common Retirement Fund now owns 14,794 shares of the company's stock worth $146,000 after acquiring an additional 4,605 shares during the period. Institutional investors own 67.99% of the company's stock.
Get Talaris Therapeutics alerts:Talaris Therapeutics Stock Performance
Shares of TALS opened at $1.39 on Wednesday. The stock has a fifty day moving average price of $2.18 and a two-hundred day moving average price of $4.29. Talaris Therapeutics, Inc. has a 52-week low of $1.16 and a 52-week high of $16.63. The company has a market cap of $57.99 million, a price-to-earnings ratio of -0.86 and a beta of 1.94.
Analyst Ratings Changes
Several equities analysts recently commented on the company. Morgan Stanley cut their target price on Talaris Therapeutics from $8.00 to $6.00 and set an "equal weight" rating for the company in a research report on Friday, September 9th. HC Wainwright assumed coverage on Talaris Therapeutics in a research report on Thursday, October 20th. They set a "buy" rating and a $18.00 target price for the company. Finally, Evercore ISI raised their target price on Talaris Therapeutics to $20.00 in a research report on Monday, August 15th.About Talaris Therapeutics
(Get Rating)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Featured Articles
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick's Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.